Breaking News
The U.S. Food and Drug Administration has granted breakthrough therapy designation to ianalumab for Sjögren’s disease.
Researchers have developed an inhalable nanotherapy called BEAT (Bispecific Exosome Activator of T Cells) that can activate the immune system against cancers resistant to current checkpoint inhibitor therapies.
A vaccine that blocks the effects of fentanyl, including overdoses, is scheduled for Phase I human trials in the Netherlands in early 2026 to assess its safety.
BioTrending
- By Amy Scanlin, MS
This revolutionary technology shows promise for addressing a myriad of challenges in medicine, but ethical dilemmas remain.
- By Diane L.M. Cook
Known as liquid gold, human plasma is proving to be a valuable ally in the fight against cancer.
- By Jim Trageser
While still in their early stages of research, FDA has approved more than a dozen complement inhibitors to treat various conditions, and there is hope that more will be on the horizon to treat others.
- By Trudie Mitschang
Virtual hospitals bring hospital-level care directly to patients' homes, representing a transformative step in healthcare delivery.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
